SCHEMBL1149335

SCHEMBL1149335

CNc1ncc2cc(-c3cc(C(=O)Nc4cccc(C(F)(F)F)c4)ccc3C)c(OC)c(-c3ccncc3)c2n1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.61
LCK P06239 9/20 0.61
MAPK14 Q16539 8/20 0.61
TEK Q02763 7/20 0.61
JAK3 P52333 4/20 0.61
BRAF P15056 2/20 0.61
YES1 P07947 1/20 0.52
DDR2 Q16832 3/20 0.50
POLB P06746 1/20 0.48
KIT P10721 4/20 0.48
ABL1 P00519 2/20 0.48
BCR P11274 1/20 0.48
DDR1 Q08345 1/20 0.48
CSF1R P07333 2/20 0.47
AURKA O14965 1/20 0.47
SRC P12931 1/20 0.47
AURKB Q96GD4 1/20 0.47
TPX2 Q9ULW0 1/20 0.47
RAF1 P04049 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1149194 0.93 KDR (0.60) KDRLCKMAPK14TEKJAK3
SCHEMBL1078814 0.91 KDR (0.61) KDRLCKMAPK14TEKJAK3
SCHEMBL1147976 0.90 KDR (0.59) KDRLCKMAPK14TEKJAK3
SCHEMBL1077653 0.89 LCK (0.58) KDRLCKMAPK14TEKJAK3
SCHEMBL1149165 0.87 LCK (0.64) KDRLCKMAPK14TEKJAK3
SCHEMBL1078560 0.85 LCK (0.61) KDRLCKMAPK14TEKJAK3
SCHEMBL1078547 0.84 LCK (0.54) KDRLCKMAPK14TEKJAK3
SCHEMBL1080552 0.84 LCK (0.64) KDRLCKMAPK14TEKJAK3
SCHEMBL1077337 0.83 KDR (0.59) KDRLCKMAPK14TEKJAK3
SCHEMBL1149330 0.83 LCK (0.63) KDRLCKMAPK14TEKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 KDR 896/4885LCK 3187/4885MAPK14 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.